• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Neurology

Addition of neuroleptics Droperidol or Olanzapine provide more rapid sedation of agitated patients than IV Midazolam alone [Ann Emerg Med.].

bys25qthea
September 18, 2012
in Neurology, Psychiatry, Surgery
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: CC

Key study points:

1.     Administration of IV droperidol or olanzapine as an adjunct to midazolam is an effective method of sedation that not associated with any increased risk of adverse events.

2.     Olanzapine appears to be safe when administered intravenously as a 5mg dose for acute agitation.

3.     IV droperidol does not appear to be associated with prolonged QTc intervals.

Primer: Agitation, a common symptom of patients seen in the ED, is often medically managed with pharmacological interventions of the benzodiazepine or neuroleptic drug classes. While several studies have compared the efficacy of these two pharmacological classes to each other, there has not been published research comparing the use of a sedative monotherapy to a combination regimen. This study strived to compare the efficacy and safety of two neuroleptics (droperidol 5mg and olanzapine 5mg) as an adjunct to midazolam in the management of highly agitated emergency department patients.

RELATED REPORTS

FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder

Propofol is associated with lower mortality in sepsis-associated encephalopathy

This [multi-center, randomized, double-blinded, controlled trial] study: Conducted in 3 large emergency departments in Australia and New Zealand between August 2009 and March 2011, this study looked at patients aged 18-65 who required parenteral drug sedation for acute agitation. Patients that had sensitivity to or contraindications against the use of any of the three intravenous drugs (midazolam, droperidol, and olanzapine), who had recently received sedatives, or who were pregnant or undergoing acute alcohol withdrawal were excluded. 336 patients were randomized to one of three groups: 1) control group (placebo-droperidol + placebo-olanzapine bolus), 2) droperidol group (droperidol 5mg + placebo-olanzapine bolus) or 3) olanzapine group (droperidol-placebo + olanzapine 5mg bolus). After the initial bolus, 2.5mg or 5mg of midazolam (for patients weighing <50kg or >50kg, respectively) was given, followed by more midazolam in incremental doses as needed to reach adequate sedation (defined as a sedation score less than or equal to 2).

Comparing several outcome measures, the authors found:

–        Time needed to reach adequate sedation was significantly shorter for the droperidol and olanzapine groups than for the control groups, with a median difference in time to sedation being 4 minutes (CI: 1-6 min) shorter for droperidol and 5 minutes (CI: 1-6 min) shorter for olanzapine.

–        The proportion of patients sedated after 10 minutes was significantly higher in the active drug groups compared to the control group, with 17.4% (CI: 3.8-30.9%) more of the droperidol group and 19.2% (CI: 5.6-32.8%) more of the olanzapine group sedated than the control group at this time point.

–        The control group required a higher median cumulative dose (10 mg) than the active drug groups (5 mg) to achieve initial sedation.

–        More patients in the control group required additional sedation within 60 minutes of initially achieving adequate sedation, and during the time period between 60 minutes after achieving adequate sedation and their ED discharge.

–        The rate of adverse events, length of ED stay, and disposition destination were not different between the three groups.

In sum: The authors of this study conclude that combination sedative regimens (droperidol+midazolam and olanzapine+midazolam) are more effective than midazolam monotherapy in treating acutely agitated patients. Combination therapies not only allow shorter time to sedation, but they require lower proportions of sedative drugs to reach sedation and a lesser need for re-sedation without presenting a higher adverse risk profile. In fact, the midazolam-only group experienced higher rates of adverse events, a finding which the authors attributed to the higher doses needed to reach and maintain adequate sedation in this group. This is the first randomized, double-blinded clinical trial comparing monotherapy to combination therapy in the treatment of acute agitation in ED patients and is also the first published clinical study supporting the use of IV olanzapine.

Written by M.K.

Click to read the study, published 9.17 in the Annals of Emergency Medicine

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCALIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Tags: agitationsedation
Previous Post

Large population based study in Denmark predicts the rates of certain adverse outcomes temporally associated with vaccine administration [BMJ]

Next Post

Acupuncture helpful for chronic pain: new meta-analysis [Arch Intern Med.]

RelatedReports

Schizophrenia collage: a calm young man, a side-view drawing of the brain, a weekly pill organizer and a potted plant
2MM Trial Briefs

FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder

November 17, 2026
Obstetric scoring systems overestimate cases of severe sepsis
Infectious Disease

Propofol is associated with lower mortality in sepsis-associated encephalopathy

February 11, 2026
Pain control after surgery collage: an older woman resting on a hospital pillow beside a teal nerve that branches at one end
Chronic Disease

Subcutaneous dexmedetomidine may safely improve refractory pain and delirium in hospice patients

January 13, 2026
Downward trend in mortality rate for antineutrophil cytoplasmic autoantibody-associated vasculitis
AI Roundup

Becton Dickinson Unveils Artificial Intelligence Powered Monitor for Surgery

May 28, 2025
Next Post

Acupuncture helpful for chronic pain: new meta-analysis [Arch Intern Med.]

“Sexting” associated with sexual risk among adolescents [Pediatrics]

Bisphenol A (BPA) linked with childhood obesity [JAMA]

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.